Peer-Reviewed Journal Details
Mandatory Fields
Cuffe, S;Dowling, CM;Claffey, J;Pampillon, C;Hogan, M;Fitzpatrick, JM;Carty, MP;Tacke, M;Watson, RWG
2011
February
Prostate
Effects of Titanocene Dichloride Derivatives on Prostate Cancer Cells, Specifically DNA Damage-Induced Apoptosis
Published
WOS: 13 ()
Optional Fields
DOUBLE-STRAND BREAKS ANTITUMOR-ACTIVITY ANTICANCER DRUGS SUBSTITUTED TITANOCENES TUMOR-CELLS IN-VITRO ATM COMPLEX MICE MECHANISM
71
111
124
BACKGROUND. While locally advanced prostate cancer is initially treatable with androgen ablation, eventually cells develop a castrate-resistant phenotype. Currently, there are no effective treatments for this form of the disease with Docetaxel only providing a small survival advantage. In this study, the effects of novel derivatives of titanocene dichloride on prostate cancer cell lines has been investigated.METHODS. Cellular effects were assessed using the crystal violet assay and the clonogenic survival assay. Cell cycle and apoptosis were assessed by propidium iodide staining. DNA damage was analyzed by comet assay and Western analysis. DNA damage response inhibition was achieved by pre-incubation with an ATM/ATR inhibitor; CGK733 and DNA-PK inhibitor; DMNB.RESULTS. These analogs caused a reduction in cell number. In particular titanocene Y and C had significant effects in all cell lines. A reduction in clonogenic survival was found in response to titanocene Y in three cell lines while the PC-3 cells exhibited increased resistance.Further analysis showed no effect on cell cycle however, the analogs were found to induce a poptosis in a dose-dependent manner in all cell lines. These analogs associate with DNA, induce DNA damage and a differential damage response. Inhibition of key regulators of this DNA damage response sensitized the PC-3 cell line to titanocene-induced apoptosis and significantly reduced the clonogenic capacity of the cells.CONCLUSION. These results demonstrate the mechanism of action of these novel titanocene dichloride analogs and their potential use in castrate-independent advanced prostate cancer. Prostate 71: 111-124, 2011. (C) 2010 Wiley-Liss, Inc.
0270-4137
10.1002/pros.21227
Grant Details
Publication Themes